Corixa ( CRXA) and GlaxoSmithKline ( GSK) said the Food and Drug Administration has approved Bexxar, a treatment for patients with non-Hodgkin's lymphoma, a form of cancer that affects the blood, bone marrow and lymphatic tissues.

The two companies will co-market Bexxar in the U.S. Corixa expects to be ready to start filling orders for Bexxar from cancer treatment centers in about 30 days.

Bexxar is a dual-action therapy that pairs the tumor-targeting ability of a cancer-killing monoclonal antibody, Tositumomab, and the therapeutic potential of radiation, Iodine-131. Combined, the agents initiate an immune response against the cancer and deliver a dose of radiation directly to tumor cells.

Non-Hodgkin's lymphoma is the sixth-leading cause of cancer-related deaths in the U.S.

Shares of Corixa were gaining 71 cents, or 10%, to $7.91 on the Nasdaq. Glaxo was down 27 cents to $40.38 on the New York Stock Exchange.

More from Stocks

3 Fierce Chinese Tech Stocks to Gamble on Right Now

3 Fierce Chinese Tech Stocks to Gamble on Right Now

Stocks Slammed on Latest Trump Tariff Fears

Stocks Slammed on Latest Trump Tariff Fears

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

Trump's Obsession With Winning His China Trade War Could Pummel Investors

Trump's Obsession With Winning His China Trade War Could Pummel Investors

How to Play Nvidia and Intel on a Trade War With China

How to Play Nvidia and Intel on a Trade War With China